The company was selected because of its nucleic acid platform which, when combined with virotherapy, has the potential to treat liver cancer by using a lipid nanoparticle delivery system.
MilliporeSigma announced on Oct. 19, 2020 that it has selected Combined Therapeutics, a pre-clinical-stage biotechnology company located in Cambridge, MA, as the North American winner of its 2020 Advance Biotech Grant Program.
The company was selected because of its nucleic acid platform which, when combined with virotherapy, has the potential to treat liver cancer by using a lipid nanoparticle delivery system, a MilliporeSigma press release said. Through the program, Combined Therapeutics will receive MilliporeSigma products and consultation in downstream processing, formulation excipients, and sterile filtration.
“We help pioneering biotech companies bring lifesaving drugs to market faster,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma, in the press release. “Combined Therapeutics’ platform shows promise to treat liver cancer, which affects thousands of people across the world each year.”
“MilliporeSigma’s expertise in large biomolecule filtration, scale-up and extensive range of excipients will play a pivotal role in moving this project forward to GMP and clinical trials,” added Romain Micol, CEO, Combined Therapeutics, in the press release. “We are honored to have been selected as the winner of MilliporeSigma’s Advance Biotech Grant, and we look forward to the collaboration.”
Source: MilliporeSigma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.